July 2, 2003
Advisory members Rick Elion and Ron Mealy said most panel members believe they need more information on the impact of Fuzeon's high cost on ADAP before recommending its approval. The two said they are leaning toward approval of Fuzeon once they are assured it would not lead to ADAP's bankruptcy.
But some AIDS activists said the city has enough money to support the new drug and the panel should have moved quickly to approve it. "People are going to die while they drag their feet," said Wayne Turner, head of ACT UP/D.C.
Roche, Fuzeon's manufacturer, has announced it would provide the drug -- normally costing $20,000 per patient per year -- to ADAP for $16,000 per patient per year -- a price that is still nearly twice as high as the next most expensive AIDS drug.
Because the committee usually meets only four times a year, it was not expected to resume its discussion on Fuzeon until August.
Joy Maatman, a representative with Roche, said that HAA official Carolyn Rachel sent her an e-mail stating that HAA had chosen not to approve Fuzeon for ADAP "at the present time." But Ivan Torres, HAA's acting administrator, said HAA is awaiting the final recommendation of its advisory committee. "We have not finalized our decision," Torres said.
06.27.03; Lou Chibbaro Jr.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.